Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31488070 | 0.92 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL760525 | 0.92 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL29234864 | 0.88 | FFAR1 (0.48) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL28509481 | 0.86 | FFAR1 (0.42) | FFAR1MAPK1 | |
| SCHEMBL18327119 | 0.86 | FFAR1 (0.40) | FFAR1 | |
| SCHEMBL1987497 | 0.83 | FFAR1 (0.49) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL31133152 | 0.82 | FFAR1 (0.37) | FFAR1 | |
| SCHEMBL2358864 | 0.81 | FFAR1 (0.45) | FFAR1IRAK4MAPK1 | |
| SCHEMBL2517121 | 0.81 | FFAR1 (0.47) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL2572488 | 0.81 | FFAR1 (0.47) | FFAR1LPLLIPGIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157392-A | Compounds targeting RNA binding proteins or RNA modification proteins | 雷多纳治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20210236493-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
| CN-110862390-A | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236493-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SLC10A1, CYP11B1, CYP11B2 | FFAR1 1375/4885LPL 2812/4885LIPG 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.